Evidence map›Paper›PMID 36883114›Full record

ArticleDrug design, development and therapy2023

Integrating Network Pharmacology and Bioinformatics to Explore the Effects of Dangshen (

Yaping Yu, Shun Ding, Xiaoqing Xu, Dongming Yan, Yonghao Fan, Banzhan Ruan, Xiaodian Zhang, Liping Zheng, Wei Jie, Shaojiang Zheng

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yaping Yu *Department of Oncology of the First Affiliated Hospital & Tumor Institute, Hainan Medical University, Haikou, 570102, People's Republic of China.
Shun Ding *Department of Otolaryngology, Head and Neck Surgery, the First Affiliated Hospital, Hainan Medical University, Haikou, 570102, People's Republic of China.
Xiaoqing Xu *Department of Oncology of the First Affiliated Hospital & Tumor Institute, Hainan Medical University, Haikou, 570102, People's Republic of China.
Dongming YanDepartment of Neurosurgery, the First Affiliated Hospital of Hainan Medical University, Haikou, 570102, People's Republic of China.
Yonghao FanDepartment of Oncology of the First Affiliated Hospital & Tumor Institute, Hainan Medical University, Haikou, 570102, People's Republic of China.
Banzhan RuanDepartment of Oncology of the First Affiliated Hospital & Tumor Institute, Hainan Medical University, Haikou, 570102, People's Republic of China.ORCID 0000-0001-9749-5203
Xiaodian ZhangDepartment of Oncology of the First Affiliated Hospital & Tumor Institute, Hainan Medical University, Haikou, 570102, People's Republic of China.
Liping ZhengDepartment of Oncology of the First Affiliated Hospital & Tumor Institute, Hainan Medical University, Haikou, 570102, People's Republic of China.
Wei JieDepartment of Oncology of the First Affiliated Hospital & Tumor Institute, Hainan Medical University, Haikou, 570102, People's Republic of China.ORCID 0000-0002-1869-1458
Shaojiang ZhengDepartment of Oncology of the First Affiliated Hospital & Tumor Institute, Hainan Medical University, Haikou, 570102, People's Republic of China.
Hainan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to explore the pharmacological mechanism of Dangshen ( Methods: The effective compounds and potential targets of Results: A total of 21 effective compounds of Conclusion:

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularCodonopsisLiver NeoplasmsLuteolinComputational BiologyEstrogen Receptor alphaNetwork PharmacologyProto-Oncogene Proteins c-aktAntineoplastic AgentsESR1 protein, humanEstrogen Receptor alphaLuteolinProto-Oncogene Proteins c-aktbioinformaticsCodonopsis pilosulahepatocellular carcinomaluteolinnetwork pharmacology

Identifiers

PMID36883114
PMCPMC9985903
OpenAlexW4322745143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.